A Long-Term Clinical Study of TS-071 as Combination Therapy in Patients With Type 2 Diabetes on insulin therapy

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080222531

Enrollment

225

Registered

2014-06-19

Start date

2014-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : TS-071 INN of investigational material : luseogliflozin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes mellitus - Has been receiving treatment with insulin preparation monotherapy at a fixed dose within the limit of approved continuously for more than 8 weeks. etc.

Exclusion criteria

Exclusion criteria: - Having non-type 2 diabetes mellitus. - Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease. etc.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026